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Abstract
Non-coding RNAs (ncRNAs) are a class of RNA molecules that do not encode proteins. ncRNAs are 
involved in cell proliferation, apoptosis, differentiation, metabolism, and other physiological processes 
as well as the pathogenesis of diseases. Cardiac fibrosis is increasingly recognized as a common final 
pathway in advanced heart diseases. Many studies have shown that the occurrence and development of 
cardiac fibrosis is closely related to the regulation of ncRNAs. This review will highlight recent updates 
regarding the involvement of ncRNAs in cardiac fibrosis, and their potential as emerging biomarkers 
and therapeutic targets. (Cardiol J 2018; 25, 6: 732–741)
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Introduction
Cardiac ﬁbrosis is a histopathologic hallmark 
of a variety of advanced heart diseases, and is an 
important event in the cardiac remodeling process, 
characterized by a disproportionate accumulation of 
extracellular matrix (ECM) components. Progres-
sive ﬁbrotic changes can be triggered by varied 
pathophysiological conditions, such as myocardial 
infarction (MI), pressure overload (e.g. hyper-
tension and aortic stenosis [AS]), hypertrophic 
cardiomyopathy (HCM), post-viral dilated cardio-
myopathy (DCM), toxic insults (e.g. alcohol or an-
thracyclines) [1], and metabolic disturbances (e.g. 
diabetes and obesity) [2, 3]. Although it initially 
serves as an adaptive remodeling, a persistent ﬁ-
brotic response will eventually result in ventricular 
dysfunction and heart failure. In addition, cardiac 
ﬁbrosis is a proposed substrate for sudden cardiac 
death (SCD) and tachyarrhythmias [4, 5].
Cellular effectors and molecular pathways 
that are implicated in the pathogenesis of cardiac 
ﬁbrosis and the transformation of cardiac ﬁbro-
blasts (CFs) to myoﬁbroblasts play a critical role in 
the development of ﬁbrosis [6]. These molecules 
include inflammatory cytokines and chemokines, 
transforming growth factor-b (TGF-b), matricel-
lular proteins, and the renin–angiotensin–aldos-
terone system. Experimental and clinical evidence 
suggests that cardiac ﬁbrotic alterations may be 
reversible [7]. Understanding the mechanisms 
responsible for the initiation, progression, and 
resolution of cardiac ﬁbrosis is crucial for enabling 
the design of anti-ﬁbrotic treatment strategies for 
patients with heart disease. Although the clinical 
use of angiotensin converting enzyme inhibitors 
(ACEI) and angiotensin II receptor antagonists can 
partially reverse this remodeling, currently, there 
are no licensed treatments for cardiac ﬁbrosis. The 
lack of an effective therapy for cardiac ﬁbrosis is 
critically responsible for its serious adverse effects. 
Thus, novel anti-ﬁbrotic strategies are urgently 
needed.
Non-coding RNAs (ncRNAs) are a class of RNA 
molecules that do not encode proteins, and function 
directly at the RNA level. Although once thought 
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to be genomic ‘junk’, ncRNAs are attracting more 
and more attention in physiological and pathological 
research ﬁelds due to their novel roles in transcrip-
tion, RNA processing and translation [8]. ncRNAs 
are divided broadly into two categories based on 
their length: short or small ncRNAs (< 200 nucleo-
tides, including microRNAs [miRs]), and long ncR-
NAs (lncRNAs, > 200 nucleotides). Circular RNAs 
(circRNAs) are another class of ncRNAs, and are 
known for their closed ring structure. ncRNAs can 
either work alone, or interact with other ncRNAs in 
mechanisms such as the competitive endogenous 
RNA (ceRNA) mechanism (as molecular sponges 
for miRs) [9, 10]. Recognition of the roles played 
by ncRNAs in human disease has unveiled new 
mechanistic understanding, and will lead to novel 
diagnostic and therapeutic approaches. Recently, 
research on the role of ncRNAs in cardiovascular 
disease, including cardiac ﬁbrosis, has developed 
rapidly. In this review, the latest research progress 
highlighting the molecular mechanism played by 
ncRNAs in cardiac ﬁbrosis and also the aim to iden-
tify novel diagnostic biomarkers and therapeutic 
strategies will be summarized.
ncRNAs in the pathogenesis  
of cardiac ﬁbrosis
In normal heart tissue the ECM components, 
primarily ﬁbrillar collagen (mainly type I colla-
gen) combined with other molecules (e.g. elastin, 
glycoproteins and proteoglycans), constitute the 
laminar scaffolds surrounding cardiomyocytes. 
This interstitial matrix is solid and flexible, holding 
the cardiomyocyte layers together, and is important 
for transmission of the contractile force. CFs play 
an important role in maintaining the integrity of the 
matrix network. However, homeostasis between 
the synthesis and degradation of ECM components 
is disrupted under pathologic conditions with trans-
differentiation and activation of myoﬁbroblasts, 
which are capable of increased ECM secretory 
activity [11]. Over-accumulation of ECM leads to 
reparative or reactive ﬁbrosis. Emerging evidence 
suggests that the abnormal expression of ncRNAs 
is linked to the physiological processes of CF dif-
ferentiation, proliferation, and induction of ﬁbrosis. 
Herein is summarized the role of ncRNAs in cardiac 
ﬁbrosis (Fig. 1).
Figure 1. ncRNAs involved in the cardiac fibrosis pathways; ncRNAs regulate cardiac fibrosis processes by targeting 
the key molecules that mediate transcription of extracellular matrix (ECM) genes and transforming growth factor-b 
(TGF-b) signaling; CTGF — connective tissue growth factor; Rho-GTP — Rho-GTPase-activating protein; ROCK — Rho 
associated coiled-coil containing protein kinase; SRF — serum response factor; MMP — matrix metalloproteinases; 
IL6 — interleukin-6; Jak1 — Janus kinase 1; Stat3 — signal transducer and activator of transcription 3; c-Fos — FBJ 
murine osteosarcoma viral oncogene homolog; Spry1 — sprouty homolog 1; ERK — extracellular signal-regulated 
kinases; DUSP5 — dual-specificity phosphatase 5.
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miRs in cardiac ﬁbrosis 
miRs are a class of endogenous single-strand-
ed ncRNAs of 18 to 24 nucleotides in length, and 
are the most widely studied ncRNAs. miRs regulate 
gene expression at the post-transcriptional level 
by targeting the 3’-untranslated region of mRNA 
sequences, thus controlling a variety of cellular 
processes essential to human health and disease 
[12]. In the heart, miRs play a crucial role in the 
mechanism of cardiac remodeling, such as cardiac 
hypertrophy, ﬁbrosis, and apoptosis. There has 
been remarkable progress in methods for the 
modulation of miR expression (e.g. miR-mimics, 
antagomiRs, and miR sponges) both in vitro and in 
vivo [13], and the understanding of pathways and 
molecules regulating cardiac ﬁbrosis has likewise 
improved signiﬁcantly.
Many miR molecules are involved in the regu-
lation of cardiac ﬁbrosis. miR-21 is one of the most 
studied anti-cardiac ﬁbrosis factors. Early work 
from Thum et al. [14] demonstrated that miR-21 
promotes cardiac ﬁbrosis by targeting extracel-
lular regulated kinase inhibitor sprouty homolog 1 
(Spry1) with stimulation of mitogen-activated 
protein kinase (MAPK) signaling in CFs. In cardiac 
fibrosis related to angiotensin II, miR-21 is tran-
scriptionally activated and targets phosphatase 
and tensin homologue (PTEN) resulting in in-
creased fibroblast survival. Osteopontin knockout 
mice are protected from miR-21 increase and 
fibrosis development due to impaired activation 
of transcription factor activator protein 1 (AP-1) 
and fibroblast [15]. A recent study performed by 
Gupta et al. [16] revealed that miR-21 together 
with cardiac fibrosis was increased in cardiac 
allografts compared with isografts. Conversely, 
both genetic and pharmacological inhibition of 
miR-21 successfully reduced fibrosis and fibrocyte 
accumulation in cardiac allografts. Further mecha-
nistic study found that overexpression of miR-21 
in monocyte cell line activated a fibrotic gene 
programme and promoted monocyte-to-fibrocyte 
transition together with activation of monocyte 
chemoattractant protein 1 via the PTEN/AP-1 
regulatory axis. Thus, inhibition of miR-21 may 
be a novel strategy to target fibrosis development 
in cardiac allografts. Moreover, miR-21 was also 
reported play a role in the inhibition process of 
interleukin-10 mediated bone marrow fibroblast 
progenitor cells homing and transdifferentiation 
to myofibroblasts in pressure-overloaded myo-
cardium. Verma et al. [17] demonstrated that 
restoration of miR-21 levels suppressed the 
interleukin-10 effects on TGF-b-induced fibrotic 
signaling in bone marrow fibroblast progenitor 
cells and thus modulates cardiac fibrosis. 
Another prominent miR that control cardiac 
ﬁbrosis is miR-29. Van Rooij et al. [18] found that 
the level of miR-29 was signiﬁcantly reduced un-
der stress, increasing the synthesis of its targets, 
including collagen, elastin, ﬁbrin, and other extra-
cellular matrix proteins, thereby promoting cardiac 
ﬁbrosis. Conversely, over-expression of miR-29 
can inhibit the synthesis of collagen and further 
reduce myocardial ﬁbrosis. Additionally, miRs are 
also involved in age-associated cardiac ﬁbrosis. 
Boon et al. [19] show that miR-34a is induced in 
the ageing heart and that in vivo silencing or ge-
netic deletion of miR-34a reduces age-associated 
cardiomyocyte cell death. Moreover, miR-34a 
inhibition reduces cell death and ﬁbrosis follow-
ing acute MI and improves recovery of myocardial 
function. Mechanistically, they identiﬁed PNUTS 
(also known as PPP1R10) as a novel direct miR-34a 
target, which reduces telomere shortening, DNA 
damage responses and cardiomyocyte apoptosis, 
and improves functional recovery after acute MI. 
Moreover, miR-34a was also involved in the regula-
tion of post-ischemic cardiac ﬁbrosis [20]. miR-34a 
was upregulated in the MI heart. In vivo, inhibition 
of miR-34a reduces the severity of experimental 
cardiac ﬁbrosis in mice. TGF-b1 increased miR-34a 
expression in CFs. Overexpressing miR-34a levels 
increased the proﬁbrogenic activity of TGF-b1 in 
CF, whereas inhibition miR-34a levels weakened 
the activity via targeting Smad4. Another study 
performed by Jazbutyte et al. [21] demonstrated 
that miR-22 also prominently upregulated during 
cardiac aging. Functionally, miR-22 overexpres-
sion induced cellular senescence and promoted 
migratory activity of CFs. Small interference RNA-
mediated silencing of mimecan in CFs mimicked 
the miR-22-mediated effects. Rescue experiments 
revealed that the effects of miR-22 on CFs were 
only partially mediated by mimecan. However, 
Hong et al. [22] revealed that miR-22 was a nega- 
tive regulator of fibrogenesis. In their study, 
miR-22 was dynamically downregulated following MI 
induced by permanent ligation of the left anterior 
descending coronary artery for 7 days, an effect 
paralleled by signiﬁcant collagen deposition. Inhibi-
tion of miR-22 resulted in increased expression of 
Col1a1, Col3a1 and ﬁbrogenesis in cultured CFs. 
Conversely, overexpression of miR-22 in cultured 
CFs signiﬁcantly abrogated angiotensin II-induced 
collagen formation and ﬁbrogenesis. Furthermore, 
they found that TGFbRI is a direct target for 
miR-22, and downregulation of TGFbR may have 
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mediated the antiﬁbrotic effect of miR-22. Since 
converse effects existing, more studies are needed 
to validate the role of miR-22 in cardiac ﬁbrosis.
Recently, Lichan Tao et al. [23] revealed that 
miR-433 plays a crucial role in the regulation 
of cardiac fibrosis and is a potential target for 
ameliorating cardiac ﬁbrosis. According to their 
investigation, miR-433 levels were increased in 
the heart tissues of myocardium with ﬁbrosis in 
DCM or MI, and miR-433 inhibition exhibited 
a cardioprotective effect by targeting the AZIN1 
and JNK1 genes through the TGF-b1, ERK, and 
p38 kinase pathways. Interestingly, miRs can also 
regulate cardiac ﬁbrotic process via preserving lipid 
raft cholesterol. Nishiga et al. [24] revealed that 
decreased miR-33, a well-studied miR in athero-
sclerosis, was associated with worsened cardiac 
function in patients with DCM. Subsequently, in 
transverse aortic constriction mice model, car-
diac ﬁbrosis was ameliorated in miR-33-deﬁcient 
hearts compared with wild-type hearts, despite no 
difference in hypertrophic responses. Moreover, 
they also found that CFs were mainly responsible 
for miR-33 expression in the heart. Deﬁciency 
of miR-33 impaired CF proliferation, which was 
considered to be caused by altered lipid raft choles-
terol content. As systemic miR-33–deﬁcient mice, 
CF–speciﬁc miR-33–deﬁcient mice also showed 
decreased cardiac ﬁbrosis induced by transverse 
aortic constriction. This study provides a novel 
angle of miR regulation in cardiac ﬁbrosis. Other 
miRs, such as miR-15, miR-30, miR-1, miR-378, 
and miR-133, that are involved in the pathogenesis 
of cardiac ﬁbrosis are summarized in Table 1.
Overall, cardiac fibrosis is a complex pro-
cess involving the coordinative interaction of 
numerous miRs. Particularly, as summarized in 
Table 1, many miRs were involved in the same 
pathologically fibrotic process, such as Let-7c, 
miR-21, miR-24, miR-29, miR-34a, miR-101, miR-
101a, and miR-433 for post-infarction fibrosis, 
and miR-15, miR-21, miR-26a, miR-125b, and 
miR-378 for pressure-overload fibrosis induced 
by transverse aortic constriction. However, the 
interactions among these miRs, the effects of al-
tering one of the miRs on the unintended targets 
and pathological processes of the disease are not 
well-studied. In addition, not only CFs, other cell 
types, such as macrophages, lymphocytes, mast 
cells, vascular endothelial cells, and cardiomyo-
cytes, also participate in the process of fibrogen-
esis. Fibroblast-enriched miRs (e.g. miR-15, and 
miR-30), can directly affect the fibrotic process, 
while non-fibroblast enriched miRs (e.g. miR-1, 
miR-378, and miR-133) may regulate it by par-
acrine mechanism. Thus, the mechanism for the 
involvement of miRs in the paracrine regulation 
of different cells during fibrogenesis needs more 
meticulous research. A specific delivery system 
or virus vehicle also lacks a design for selective 
manipulation of miRs in cardiac myocytes and 
nonmyocytes.
lncRNAs in cardiac ﬁbrosis
lncRNAs, a class of transcripts larger than 200 
nucleotides, have a more heterogeneous distribu-
tion in the genome, with nested and overlapping, 
sense and antisense transcripts. They had an 
mRNA-like structure, as they can also incorporate 
exons, have a 3’ poly-A tail and CpG islands, and 
display alternate splicing [25]. However, lncRNAs 
generally do not encode proteins, share less se-
quence conservation, and show lower expression 
levels. They participate in diverse biological pro-
cesses, including histone modiﬁcation, transcript 
regulation, mRNA fragmentation, endo-sponge 
activity, and direct protein interaction, and play 
important roles in various diseases. Recently, there 
have been signiﬁcant advances in the identiﬁcation 
of lncRNAs involved in cardiac ﬁbrosis (Table 2). 
Tao et al. [26] revealed that overexpression 
of lncRNA H19, a highly abundant and conserved 
imprinted gene, increased the proliferation of CFs 
and the resulting cardiac ﬁbrosis by inhibiting 
dual-speciﬁcity phosphatase 5 (DUSP5), whereas 
H19 silencing induced the opposite effect. Fur-
ther mechanistic studies unveiled that the lncRNA 
H19 promotes CF proliferation and ﬁbrosis partly 
through the repression of DUSP5 and the activation 
of p-ERK1/2, a well-known pro-proliferative and pro-
ﬁbrotic signaling pathway [26]. The same group also 
recently investigated the role and function of lncRNA 
growth arrest-speciﬁc 5 (GAS5) in cardiac ﬁbrosis, 
and demonstrated that GAS5 plays a suppressive role 
in cardiac ﬁbrosis via negative regulation of miR-21 
[27]. Furthermore, they found that the modulation 
of miR-21 regulated the expression of matrix metal-
loprotease-2 (MMP-2) via a phosphatase and tensin 
homologue (PTEN) pathway in CFs.
Another study demonstrated the potential 
role of NR024118 in CF showed that angiotensin II 
dynamically regulated the expression of lncRNA-
-NR024118 and Cdkn1c in CFs [28]. Huang et al. 
[29] observed an altered lncRNAs expression in 
ischemic cardiomyopathy and revealed that mouse 
CF-enriched lncRNAs n379599, n379519, n384648, 
n380433 and n410105 regulate the ﬁbrosis related 
genes expression via targeting TGF-b signaling 
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pathway. In a mice model of myocardial infarction, 
Qu et al. [30] have reported an altered lncRNAs 
expression pattern. Furhtermore, using bioin-
formatics analysis, they found lncRNA-NONM-
MUT022554 may affect ECM-receptor interactions 
and the phosphoinositid-3 kinase/protein kinase B 
Table 1. miRs involved in the regulation of cardiac fibrosis.
miRs name Modulation Targets/signaling pathway Pathological factors/species Effects Ref.
Let-7c Up Activate Oct4 and Sox2 MI/mouse; NRCFs Pro- [34]
Let-7i Down Suppress interleukin-6  
and collagens
Ang II/mouse; NRCFs Anti- [35]
miR-1 Down Activate Fibullin-2/MAPK AAB/rat Anti- [36]
miR-9 Down Suppress TGFb receptor II High glucose/human CFs Anti- [37]
miR-15 Up Suppress TGFb receptor I,  
p38, endoglin, Smad3/7 
TAC/mouse Anti- [38]
miR-21 Up Activate sprouty homologue  
1/ERK-MAP kinase
TAC/mouse Pro- [14]
Suppress TGFb receptor III/ 
/p-Smad3
MI/mouse [39]
Activate osteopontin/PTEN  
and Smad7
Ang II/mouse [15]
Activate PTEN/AP-1 Allografts/mice; monocyte [16]
miR-22 Up Suppress mimecan (osteoglycin) Aging/mouse; NRCFs Pro- [21]
Down Suppress TGFb receptor I Ang II/mouse Anti- [22]
miR-24 Down Suppress Furin/TGF-b MI/mouse Anti- [40]
miR-26a Down Suppress collagen I  
and CTGF
Ang II/NRCFs 
TAC/IkBa tg mouse
Anti- [41]
miR-29 Down Activate collagens, fibrillins,  
and elastin
MI/mouse and human Anti- [18]
miR-29b Down Suppress multiple collagens, 
MMP, IGF-1, LIF, and PTX-3
Mouse CFs [42]
miR-30, 133 Down Activate CTGF Renin-2 tg rat Anti- [43]
miR-34a Up Suppress PNUTS Aging, MI/mice, human Pro- [19]
Activate Smad4 MI/mouse [20]
miR-101 Down Suppress c-Fos/TGF-b1 Ang II, MI/rat Anti- [44]
miR-101a Down Suppress TGFb receptor I,  
p-Smad3
MI, hypoxia/rat Anti- [45]
miR-122 Down Activate TGF-b1 AS/human Anti- [46]
miR-125b Up Suppress Apelin, p53 TAC, AngII/mouse; Pro- [47]
human CFs
miR-133a Down Suppress Snai1 Mouse embryonic fibroblasts Anti- [48]
Down Suppress Col1A1 Ang II/rat [49]
miR-145 Up Suppress TGFb receptor II Smooth muscle cells;  
Ang II/mouse
Anti- [50]
miR-208a Up Activate endoglin Aorta-caval shunt/rat Pro- [51]
miR-378 Down Activate RTK, GRB-2/TGFb AngII, TAC/mouse; NRCFs Anti- [52]
miR-433 Up Suppress AZIN1 and JNK1/ 
/TGF-b1, ERK, p38 kinase,  
and Smad3 
MI/mice; NRCFs Pro- [23]
NRCFs — neonatal rat cardiac fibroblasts; Ang II — angiotensin II; Col — collagen; ERK — extracellular signal-regulated kinases; MAPK — 
mitogen-activated protein kinase; LIF — leukemia inhibitory factor; IGF-1 — insulin-like growth factor 1; PTX-3 — pentraxin 3; c-Fos — FBJ 
murine osteosarcoma viral oncogene homolog; MI — myocardial fibrosis; TAC — transverse aortic constriction; AAB — ascending aortic 
banding; TGF-b — transforming growth factor-b; MMP — matrix metalloproteinases; CTGF — connective tissue growth factor; PTEN —  
phosphatase and tensin homologue; AS — aortic valve stenosis; RTK — receptor-tyrosine kinase
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Table 2. lncRNAs and circRNAs involved in the regulation of cardiac fibrosis.
ncRNAs name Modulation Targets/signaling pathway Pathological factors/species Effects Ref.
H19 Up Suppress DUSP5 and  
activate p-ERK1/2
ISO/rat; TGF-b1/NRCFs Pro- [26]
GAS5 Down Suppress miR-21 / PTEN/MMP-2 ISO/rat; TGF-b1/NRCFs Anti- [27]
NR024118 Down Suppress cell cycle  
inhibitor Cdkn1c
Ang II/adult rat CFs ? [28]
n379599, 
n379519, 
n384648, 
n380433 and 
n410105
Up Activate ECM genes (e.g. Col8A1, 
Col3A1, and fibronection)/TGF-b 
pathway (PAI-1, Snai1, Snai2, 
and p-Smad2/3)
ICM/human; mouse CFs Pro- [29]
NONM-
MUT022554
Up Activate ECM–receptor  
interactions and PI3K-Akt
MI/mouse ? [30]
circRNA_010567 Up Suppress miR-141/TGF-b1 Diabetic mouse Pro- [32]
circRNA_000203 Up Suppress miR-26b-5p/colla2  
and CTGF
AngII/mouse CFs Pro- [33]
DUSP5 — dual-specificity phosphatase 5; PTEN — phosphatase and tensin homologue; MMP — matrix metalloproteinases; NRCFs — neona-
tal rat cardiac fibroblasts; ERK — extracellular signal-regulated kinases; ECM — extracellular matrix; ICM — ischemic cardiomyopathy; ISO — 
isoproterenol; TGF-b — transforming growth factor b; MI — myocardial fibrosis; PI3K-AKT — phosphoinositid-3 kinase/protein kinase B; CTGF 
— connective tissue growth factor; Ang II — angiotensin II
(PI3K-Akt) signalling pathway and thus regulate 
cardiac ﬁbrosis. However, most of these studies 
were performed in isolated cells or animal models 
and lack in-depth mechanistic research. Since 
poorly conservation between species, the role 
of these lncRNAs in the ﬁbrotic pathogenesis of 
patients warrant further investigation.
circRNA in cardiac ﬁbrosis
Initially, it was thought that circRNAs were 
produced by RNA splicing errors; however, these 
ncRNAs have recently become a new hot spot 
for research. Depending on their genomic struc-
tures, circRNAs can be classified into one_exon, 
annot_exon, intronic, exon_intron, intergenic, 
and antisense [31]. Each type has distinctive 
properties, including the potential for circle 
ampliﬁcation of RNA, the ability to reorganize 
the order of genomic information, protection from 
exonucleases, and constraining RNA folding. With 
the advent of deep sequencing technology and 
advanced data analysis methods, the regulatory 
mechanisms of circRNAs have been identiﬁed, 
including sponging of miRs, regulating adjacent 
gene expression, and binding to speciﬁc proteins 
to alter their cellular localization. 
Zhou et al. [32] showed that circRNA-010567 
promotes myocardial fibrosis via suppressing 
miR-141, by targeting TGF-b1 in a diabetic mouse 
model. In another recent study, circRNA_000203 
identified from CFs has pro-ﬁbrotic effects as 
a miR-26-5p sponge, thus blocking the interac-
tions between miR-26-5p and its target ﬁbrosis-
associated genes Col1a2 and connective tissue 
growth factor (CTGF) [33]. Despite all of this, 
knowledge of circRNAs is extremely limited and 
their regulatory role in cardiac ﬁbrosis remains to 
be fully understood.
ncRNAs as emerging biomarkers  
for cardiac ﬁbrosis
The evaluation of cardiac ﬁbrosis can serve as 
key indicators for risk stratiﬁcation and guide SCD 
prevention. Histopathological analysis is the gold 
standard to visualize extracellular compartment of 
myocardium and quantify myocardial ﬁbrosis. How-
ever, the clinical application of this invasive method 
is largely limited. Cardiac magnetic resonance 
(CMR) is emerging as a gold standard among the 
non-invasive imaging modalities to identify these 
pathological changes. Nonetheless, this methodol-
ogy is associated with a number of intrinsic limi-
tations. For example, ionizing, extensive imaging 
time, and this method cannot be used for patients 
with implanted metal devices. Therefore, there is 
an ongoing search for novel serum biomarkers of 
cardiac ﬁbrosis assessment. It has become evident 
that ncRNAs, especially miRs, are potential novel 
biomarkers for cardiovascular disease due to their 
ideal characteristics. ncRNAs can be released into 
the blood from dying cells or actively secreted from 
living cells under stimulation. Since combined with 
lipoprotein or existed in vesicles, miRs show a 
high degree of stability in the circulation, and can 
be easily detected [53]. 
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Studies show that miR 21 and miR-19b might 
be useful to estimate intracardiac ﬁbrotic processes 
in patients with AS. Villar et al. [54] revealed that 
both the myocardial and plasma levels of miR 21 
were signiﬁcantly higher in AS compared with 
healthy individuals. miR-21 overexpression was 
conﬁned to interstitial cells and absent in cardio-
myocytes. Moreover, circulating levels of miR-21 
together with miR-21 target genes predicted the 
variance of myocardial collagen expression levels. In 
another study, investigators analyzed the potential 
associations of 7 myocardial ﬁbrosis-related miRs 
with the degree of collagen ﬁbril cross-linking (CCL) 
and the enzyme lysyl oxidase (LOX) responsible for 
CCL in 28 patients with AS [55]. From the studied 
miRs only miR-19b presented a direct correlation 
between myocardial and blood samples. In addition, 
myocardial and serum miR-19b were inversely cor-
related with CCL, LOX, and left ventricular stiffness 
in AS patients. In in vitro studies miR-19b inhibition 
increased connective tissue growth factor protein 
and LOX protein expression in human ﬁbroblasts. 
However, their use needs to be veriﬁed in a large 
cohort. Moreover, their ability to characterize the 
degree of cardiac ﬁbrosis also needs to be further as-
sessed, combined with CMR or myocardial biopsies.
Another cardiac pathology usually associated 
with high levels of cardiac ﬁbrosis is HCM. Among 
a set of 21 different miRs detected in the plasma 
of patients with HCM, only miR 29a correlated 
with CMR detected levels of cardiac ﬁbrosis. In 
this study, and in contrast to patients with AS, 
miR 21 levels did not correlate with the cardiac 
ﬁbrosis process (although miR 21 levels were still 
increased in patients with HCM) [56]. Another 
study attempted to determine the plasma levels 
of miRs proﬁle in HCM patients with diffuse myo-
cardial ﬁbrosis (deﬁned as T1 ≥ 470 ms of CMR) 
by miR array analysis. After polymerase chain 
reaction validation, a total of 11 miRs, including 
miR-21-5p and miR-29a-3p, were significantly 
inversely correlated with post-contrast T1 val-
ues [57]. The involvement of miRs as potnetial 
biomarkers for cardiac ﬁbrosis was also demon-
strated in patients with DCM. Rubiś et al. [58] 
investigated relationships between circulating 
levels of a set of 5 different miRs and ECM ﬁbrosis 
assessed by endomyocardial biopsy in patients with 
DCM. Circulating miR-26 and miR-133a were found 
to be independently associated with ﬁbrosis. 
In conclusion, although these reports dem-
onstrated that circulating miRs provide attractive 
candidates as putative biomarkers for cardiac 
ﬁbrosis in a variety of cardiovascular diseases, the 
results need to be validated in larger cohorts. In 
addition, its prognostic value for adverse events, 
such as SCD and ventricular dysfunction, are lack-
ing. Recently, no study has reported if the circulat-
ing levels of lncRNAs and circRNAs are sufﬁcient 
to serve as biomarkers for cardiac ﬁbrosis. This 
requires urgent attention in future studies.
ncRNAs as potential therapeutic  
targets for cardiac ﬁbrosis
RNA therapeutics is the use of sophisticated 
chemically synthesized/modiﬁed nucleic acids de-
livered via ‘carrier’ molecules (e.g. liposomes and 
nanoparticle, and/or ligands), or produced in vivo 
by recombinant viral vectors. Viral vectors have 
the capacity to continuous transcript a therapeutic 
RNA sequence, whereas chemical synthesis allows 
introduction of RNA modiﬁcations that cannot be 
generated biologically [53]. Currently the most ad-
vanced and frequently used RNA therapeutics are 
RNA interference, target gene silencing by small 
interfering RNAs and related structures. 
For example, the RNA interference drug ablat-
ing proprotein convertase subtilisin/kexin type 9 
(PCSK9), which aims to lower the low density 
lipoprotein cholesterol level, has an ongoing clini-
cal phase 2 trial [59]. miR therapeutics for ablation 
or enhancement of miR functions by miR mimics 
or antagomiRs is another hotspot approach. With 
recent developments in the afﬁnity and speciﬁc-
ity of delivery systems, experimental studies and 
preclinical or clinical research has made signiﬁcant 
progress in cancer therapy [60]. Although there are 
no ongoing clinical trials for investigating the role 
of miRs in cardiac ﬁbrotic changes, the technical 
processes used and research progress achieved in 
these trials also provides a reference and basis for 
ncRNA-therapeutic modulation of cardiac ﬁbrosis.
Since high targeting efﬁcacy and speciﬁcity 
is critical for therapeutic success, local delivery, 
such as catheter-based miR eluting stents and 
light-induced antimiR activation, is particularly 
desirable, in order to arrive at the cells of interest. 
Adeno-associated virus serotype 9 (AAV9) denotes 
a cardiac-targeting recombinant viral vector, which 
is highly selective for cardiac myocytes. Ramanu-
jam et al. [61] developed a viral vector-based strat-
egy for gene targeting of nonmyocyte cardiac cells 
in vivo and compared global to cardiac myocyte-spe-
ciﬁc and nonmyocyte-speciﬁc deletion of miR-21 
in chronic left ventricular pressure overload. In 
their study, AAV9 and moloney murine leukemia vi-
rus (MMLV) were engineered to encode improved 
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Cre recombinase for cardiac myocyte-specific 
deletion and nonmyocyte ablation in miR-21fl/fl 
mice. Pericardial injection of MMLV-improved Cre 
recombinase to neonates achieved highly selective 
genetic ablation of miR-21 in nonmyocyte cardiac 
cells, identiﬁed as CFs and endothelial cells. Upon 
left ventricular pressure overload, cardiac function 
was only preserved in mice with miR-21 deﬁciency 
in nonmyocyte cardiac cells, but not in mice with 
global or cardiac myocyte-speciﬁc ablation. This study 
encouraged further development of antimiR therapy 
toward cellular tropism. The “off-target” effects of 
modulating ncRNAs as novel therapeutic targets is 
also worth-noting, since multiple mRNA genes and 
signaling pathways can be targeted by one miR.
In light of the current lack of therapeutic options 
for anti-ﬁbrotic treatment as well as the key players 
of ncRNAs in cardiac ﬁbrosis, ncRNAs have now 
fundamentally expanded our spectrum of therapeutic 
options. In the past decade, using different animal 
models, scientists could use loss or gain of ncRNA 
function-strategies to treat, and in certain cases, re-
verse cardiac ﬁbrosis (as summarized in Tables 1 and 2). 
However, selective targeting of CFs, key players in 
the pathology of cardiac ﬁbrosis, in humans is cur-
rently not possible. The heterogeneity in the function 
of ncRNAs, the disease phenotype, and the thera-
peutic response to ncRNAs, which exists between 
animal models and humans, has made the transition 
from rodents to humans challenging. Further studies 
are urgently needed to fully understand the functions 
of ﬁbrosis-related ncRNAs, and to translate these 
fascinating results to clinical applications.
Conclusion and clinical perspectives
Despite its adverse effects, there is currently 
no efficient therapeutic approach available for 
cardiac ﬁbrosis. Increasing evidence indicates that 
ncRNAs play an important role in the pathogenesis 
of cardiac ﬁbrosis, and they therefore have poten-
tial as novel biomarkers and therapeutic targets. 
Various in vitro and animal ncRNA studies have 
demonstrated fascinating results; however, no 
ongoing clinical trials investigating the role of 
ncRNAs in cardiac ﬁbrotic changes are currently 
underway. Despite obstacles, modulating ncRNAs 
has promising potential as an attractive therapeutic 
strategy for treating cardiac ﬁbrosis, particularly 
with the remarkable progress in the development 
of ncRNA drug design and delivery.
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